Adularia develops tumor‑targeted immunotherapies that harness microbiome‑derived immune regulatory pathways. By integrating multi‑omics data and AI‑driven molecule design, the company creates small‑molecule agents aimed at enhancing the body’s natural anti‑cancer response. Its platform focuses on precise activation of innate immunity to improve efficacy and reduce side effects in oncology patients.
Funding
$161.7K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
VKFounders
Product
Problem
Colorectal cancer treatment faces challenges in effectively targeting the tumor microenvironment and eliciting a robust immune response, which can limit treatment efficacy and negatively impact patient outcomes. Current therapies may not fully address the complex interplay between the gut microbiome, immune system, and tumor cells.
Solution
Adularia is developing precision cancer immunotherapies by leveraging insights into the symbiotic relationship between gut microbes and the immune system. The company has identified a novel molecular mechanism involving a microbial metabolite that activates tumor-residing macrophages, triggering cytokine release and a potent anti-tumor immune response. Adularia's approach aims to enhance the body’s natural defenses to fight cancer more effectively with a tumor-targeted immunotherapy designed for improved target activation and maximized efficacy. Their multi-omics approach guides the selection of target populations, and AI-powered molecule design optimizes their therapeutic candidates.
Target Audience
The primary target audience includes oncology researchers and clinicians focused on developing and applying innovative immunotherapies for colorectal cancer, as well as patients seeking more effective and targeted treatment options.
Features
- Identification of novel therapeutic targets through microbiome-based research
- Focus on a novel immune-regulatory pathway for oncology
- Development of tumor-targeted immunotherapies
- Multi-omics guided selection of target population
- AI-powered molecule design